Drug Trial Radar · NCT03260894
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Dec 7, 2017
Primary completion
Aug 22, 2018
Study completion Jun 4, 2025
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Aug 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
Conditions
- Renal Cell Carcinoma (RCC)
Interventions
PembrolizumabDrug
Pembrolizumab 200 mg administered intravenously every 3 weeks.
EpacadostatDrug
Epacadostat 100 mg administered orally twice daily.
SunitinibDrug
Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
PazopanibDrug
Pazopanib 800 mg administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)Time frame: up to approximately 8 months
Locations
140 sites in 20 countries. Site status is shown where the registry gives one.
Pinnacle Oncology Hematology
Scottsdale, Arizona
Scottsdale Healthcare
Scottsdale, Arizona
Arizona Oncology Associates PC- HOPE
Tucson, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
UC Irvine Comprehensive Cancer Center/Chao Family Comprehensive Cancer Center
Orange, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Woodlands Medical Specialists, PA
Pensacola, Florida
Northside Hospital
Atlanta, Georgia
Atlanta Cancer Care - Conyers
Conyers, Georgia
Northwest Georgia Oncology Centers Pc
Marietta, Georgia
Rush University Medical Center
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Southeast Nebraska Hematology & Oncology Consultants, P.C.
Lincoln, Nebraska
New York Oncology Hematology P.C
Albany, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon
University of Tennessee Erlanger Oncology & Hematology
Chattanooga, Tennessee
The West Clinic, P.C.
Germantown, Tennessee
US Oncology and Research
The Woodlands, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Huntsman Cancer Institute
Salt Lake City, Utah
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Roanoke, Virginia
Shenandoah Oncology, P.C.
Winchester, Virginia
Fiona Stanley Hospital
Murdoch, Australia
Canberra Hospital
Garran, Australian Capital Territory, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Cabrini Health
Malvern, Victoria, Australia
Centro Avancado de Tratamento Oncologico - CENANTRON -
Belo Horizonte, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil
Centro de pesquisa Porto Alegre
Porto Alegre, Florianopolis, Brazil
Fundacao Pio XII - Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Hospital Sao Jose
São Paulo, São Paulo, Brazil
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Kingston Health Sciences Centre - KGH Site
Kingston, Ontario, Canada
Sunnybrook Health Sciences, Odette Cancer Centre
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.